Marc Scheetz

Has grant

Professor of Pharmacy Practice and Pharmacology

Midwestern University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Marc Scheetz is a Professor of Pharmacy Practice and Pharmacology at Midwestern University, USA. His research focuses on pharmacokinetics and pharmacodynamics, particularly in critically ill patients, as evidenced by his recent publications on nephrotoxicity, dosing strategies for antibiotics, and the safety of various infusion methods. He is actively contributing to the understanding of drug interactions and kidney function indicators in the context of antibiotic treatment.

Recent Grants

Grant: Close

Assessment of MODS and Personalized Exposures of Antibiotics

Open Date: 2021-09-22

Close Date: 2026-08-31

Grant: Close

Quantifying renal injury among the most commonly used clinical antibiotic combinations

Open Date: 2020-01-16

Close Date: 2022-12-31

Grant: Close

Optimizing clinical use of Polymyxin B: Teaching an old drug to treat superbugs

Open Date: 2015-06-19

Close Date: 2020-05-31

Grant: Close

Elucidation of an informed drug dosing scheme to minimize kidney injury

Open Date: 2014-04-01

Close Date: 2018-03-31

Grant: Close

Patient-Oriented Research on Hospital-Acquired Pathogens

Open Date: 2013-07-10

Close Date: 2018-06-30

Articles (28)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (15)

Manjunath Pai

Professor and Chair

University of Michigan

UNITED STATES

Marc Scheetz

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (28)

Protamine protects against vancomycin-induced kidney injury

Oral Cephalexin Population Pharmacokinetics and Target Attainment Analysis in Infants 7-60 Days Old

Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity

Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia

Individual target pharmacokinetic/pharmacodynamic attainment rates among cefepime-treated patients admitted to the ICU with hospital-acquired pneumonia with and without ECMO

Effect of Pseudonephrotoxicity on Apparent Acute Kidney Injury Incidence and Severity

Response to Cojutti and Pea, “Is it Time to Move From Intermittent to Continuous Infusion Administration of Vancomycin?”

Big Data Bayesian Truths: No Vancomycin Trough Concentration Target Is Sufficiently Precise for Safety or Efficacy

Meta-analysis on safety of standard vs. prolonged infusion of beta-lactams

Antimicrobial therapeutic drug monitoring in critically ill adult patients – An international perspective on access, utilisation, and barriers

In-vitro and in-vivo assessment of nirmatrelvir penetration into CSF, central nervous system cells, tissues, and peripheral blood mononuclear cells

Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections

Impact of humanized vancomycin infusion on kidney function and kidney injury in a translational rat model

Bioanalysis of Six Antibiotics from Volumetric Microsamples: A New Tool for Precision Dosing in Critically ill Children

Past, present, and future biomarkers of kidney function and injury: The relationship with antibiotics

Flucloxacillin worsens while imipenem‐cilastatin protects against vancomycin induced kidney injury in a translational rat model

Making the case for precision dosing: visualizing the variability of cefepime exposures in critically ill adults

Iohexol-Measured Glomerular Filtration Rate and Urinary Biomarker Changes between Vancomycin and Vancomycin Plus Piperacillin-Tazobactam in a Translational Rat Model

Genomics of Aminoglycoside Resistance in Pseudomonas aeruginosa Bloodstream Infections at a United States Academic Hospital

Pharmacokinetic and Biomarker Quantification Studies on Vancomycin-Loaded PEGylated Liposomes and Its Potential to Reduce Vancomycin-Induced Kidney Injury: A Rat Study

Nephrotoxin Stewardship Alongside Antimicrobial Stewardship

Impact of Vancomycin Loading Doses and Dose Escalation on Glomerular Function and Kidney Injury Biomarkers in a Translational Rat Model

Adequacy of cefepime concentrations in the early phase of critical illness: A case for precision pharmacotherapy

Cefazolin in the treatment of central nervous system infections: A narrative review and recommendation

Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial

Individual meropenem epithelial lining fluid and plasma PK/PD target attainment

Contemporary pharmacologic treatments of MRSA for hospitalized adults: rationale for vancomycin versus non-vancomycin therapies as first line agents

Population pharmacokinetic model of cefepime for critically ill adults: a comparative assessment of eGFR equations

Collaborators (15)

Manjunath Pai

Veena Venugopalan

Lisa Hong

Roxane Rohani

Duxin Sun

Gwendolyn Pais

Michael N. Neely

Athena Zuppa

Mohammad Alshaer

Nathaniel Rhodes

Sonya C. Tang Girdwood

Medha Joshi

Majdi N. Al-Hasan

Sean Avedissian

Alan R. Hauser

Make your next move.